Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine
Journal of General Virology · 2025
DOI: 10.1099/jgv.0.002157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of General Virology, 2025. Verfasst von Martina Pfranger und 23 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Hemorrhagic Fevers, Viral, Immunogenicity, Vaccine, Lassa Fever, Lassa virus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovate UK.
Abstract (Originalsprache)
A multivalent vaccine targeting high-consequence infectious diseases in Sub-Saharan Africa (SSA), which are linked to high mortality, morbidity and overlapping clinical manifestations, would significantly improve health security and economic stability in this region. Trivalent vector vaccines were devised to deliver digitally optimized versions of Orthoebolavirus, Orthomarburgvirus glycoproteins (GPs) and a Lassa mammarenavirus (LASV) nucleoprotein (NP) by a single Modified Vaccinia Ankara (MVA) known to protect against mpox virus (MPXV) along with a matched DNA vaccine. Three immunizations in mice and Hartley guinea pigs with MVA only or a DNA prime followed by two MVA administrations induced comparable levels of binding antibodies and LASV-specific T-cells, respectively. While DNA priming mitigated MVA-specific antibody responses, GP- and NP-specific antibodies developed already after a single MVA vaccination. Although a post-outbreak Ebola virus vaccine is available, outbreaks by other filoviruses, annual LASV epidemics and increased incidence of MPXV infections support the rationale for an MVA-based trivalent haemorrhagic fever vaccine for endemic and high-risk human populations in SSA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
- Department of Veterinary Medicine, Lab of Viral Zoonotics, University of Cambridge, Cambridge, UK.
- One Virology, Wolfson Centre for Global Virus Research, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.
- DIOSynVax Ltd™, Cambridge, UK.
- Microsoft Health Futures, Redmond, USA.
- London School of Hygiene and Tropical Medicine, London, UK.
Förderung
- Innovate UK
Zitieren
APA
Pfranger, M., Krause, N., Asbach, B., Meier, J., Carnell, G., Scheer, L., Kalender, A., Brenner, D., Tonks, P., Frost, S., Wright, E., Jordan, I., Kennedy, E., Hewson, R., Blacklaws, B., Chan, A., Parthasarathy, S., Dowall, S., Carroll, M., …, & Wagner, R. (2025). Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine. Journal of General Virology. https://doi.org/10.1099/jgv.0.002157
Vancouver
Pfranger M, Krause N, Asbach B, Meier J, Carnell G, Scheer L, et al. Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine. Journal of General Virology. 2025. doi:10.1099/jgv.0.002157
BibTeX
@article{Pfranger2025,
author = {Pfranger, Martina and Krause, Nina and Asbach, Benedikt and Meier, Johannes and Carnell, George and Scheer, Lara and Kalender, Anja and Brenner, David and Tonks, Paul and Frost, Simon and Wright, Edward and Jordan, Ingo and Kennedy, Emma and Hewson, Roger and Blacklaws, Barbara and Chan, Andrew and Parthasarathy, Srivatsan and Dowall, Stuart and Carroll, Miles and Sandig, Volker and Fedosyuk, Sofiya and Kinsley, Rebecca and Heeney, Jonathan and Wagner, Ralf},
title = {Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine},
journal = {Journal of General Virology},
year = {2025},
doi = {10.1099/jgv.0.002157}
}
EUVIMED